Experienced in Obsessive-Compulsive Disorder (OCD)

Dr. Scott T. Aaronson

Psychiatry
6501 N Charles St, 
Baltimore, MD 
Accepting New Patients
Experienced in Obsessive-Compulsive Disorder (OCD)
6501 N Charles St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Aaronson is a Psychiatrist in Baltimore, Maryland. Dr. Aaronson is rated as an Experienced provider by MediFind in the treatment of Obsessive-Compulsive Disorder (OCD). His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Post-Traumatic Stress Disorder (PTSD), Obsessive-Compulsive Disorder (OCD), and Deep Brain Stimulation. Dr. Aaronson is currently accepting new patients.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Obsessive-Compulsive Disorder (OCD).

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

6501 N Charles St, Baltimore, MD 21204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Enrollment Status: Terminated
Publish Date: December 20, 2024
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Enrollment Status: Completed
Publish Date: April 24, 2023
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Enrollment Status: Unknown
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Psilocybin
Study Phase: Phase 2
An Open Label Trial of TMS Therapy for Bipolar Depression
An Open Label Trial of TMS Therapy for Bipolar Depression
Enrollment Status: Completed
Publish Date: June 01, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Multicenter, Double-Blind, Sham-Controlled Adaptive Design Study to Confirm the Safety and Efficacy of NEST sTMS in Subjects With Major Depressive Disorder Who Have Not Responded to at Least One Antidepressant Medication in the Current Episode
A Prospective, Multicenter, Double-Blind, Sham-Controlled Adaptive Design Study to Confirm the Safety and Efficacy of NEST sTMS in Subjects With Major Depressive Disorder Who Have Not Responded to at Least One Antidepressant Medication in the Current Episode
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Device
Study Phase: Not Applicable
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
View 12 Less Clinical Trials

70 Total Publications

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
Journal: Journal of affective disorders
Published: October 11, 2025
Similar Doctors
Elite in Obsessive-Compulsive Disorder (OCD)
Dr. Gerald Nestadt
Psychiatry
Elite in Obsessive-Compulsive Disorder (OCD)
Dr. Gerald Nestadt
Psychiatry
600 N Wolfe St, 
Baltimore, MD 
 (6.6 miles away)
410-955-5104
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gerald Nestadt is a Psychiatrist in Baltimore, Maryland. Dr. Nestadt is rated as a Distinguished provider by MediFind in the treatment of Obsessive-Compulsive Disorder (OCD). His top areas of expertise are Obsessive-Compulsive Disorder (OCD), Tourette Syndrome, Anorexia, and Schizophrenia. Dr. Nestadt is currently accepting new patients.

Elite in Obsessive-Compulsive Disorder (OCD)
Dr. Marco A. Grados
Psychiatry
Elite in Obsessive-Compulsive Disorder (OCD)
Dr. Marco A. Grados
Psychiatry

Kennedy Krieger Associates

707 N Broadway, 
Baltimore, MD 
 (6.5 miles away)
443-923-9200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Marco Grados is a Psychiatrist in Baltimore, Maryland. Dr. Grados is rated as a Distinguished provider by MediFind in the treatment of Obsessive-Compulsive Disorder (OCD). His top areas of expertise are Tourette Syndrome, Obsessive-Compulsive Disorder (OCD), Anorexia, and Attention Deficit Hyperactivity Disorder (ADHD). Dr. Grados is currently accepting new patients.

Distinguished in Obsessive-Compulsive Disorder (OCD)
Dr. Andrew C. Warren
Psychiatry
Distinguished in Obsessive-Compulsive Disorder (OCD)
Dr. Andrew C. Warren
Psychiatry

Sheppard Pratt Physicians PA

6501 N Charles St, 
Baltimore, MD 
 (0.1 miles away)
410-938-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Warren is a Psychiatrist in Baltimore, Maryland. Dr. Warren is rated as an Advanced provider by MediFind in the treatment of Obsessive-Compulsive Disorder (OCD). His top areas of expertise are Obsessive-Compulsive Disorder (OCD), Schizoaffective Disorder, Schizophrenia, and Bipolar Disorder (BPD). Dr. Warren is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aaronson's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile